Original Articles
Copyright ©The Author(s) 2001.
World J Gastroenterol. Apr 15, 2001; 7(2): 228-234
Published online Apr 15, 2001. doi: 10.3748/wjg.v7.i2.228
Table 2 Detectability of HCV-RNA in serum and PBMC during an IFN-α2a therapy
PatientNo.Before therapy
During therapy
After therapy
HCV-RNA concentration (copy/mL) (HCV-RNA: serum pos./ PBMC pos.)HCV-RNA concentration (copy/mL) (HCV-RNA: serum pos./ PBMC n.d.)HCV-RNA concentration (copy/mL) (HCV-RNA: serum pos./ PBMC n.d.)HCV-RNA concentration (copy/mL) (HCV-RNA: serum pos./ PBMC pos.)
164717< 6001)1)
214300< 6001)1)
3132224< 6002)167898
41076846242)135242
516171814041)1)
656209031108938861
718309120411)1)
8172345< 600196086679
9295427752)770810
102190181138< 6007240
1142601< 6001)1)
12237335< 6001)1)
132509722631)1)
1455390111442)4706
158689962)627349918